BioSpace News Archive

Johnson & Johnson announced that Ashley McEvoy, Executive Vice President, Worldwide Chairman of MedTech, informed the company on October 20, 2023, that she is stepping down from her position to pursue other opportunities.

Procaps Group, a leading integrated LatAm healthcare and pharmaceutical conglomerate, announced the appointment of one new member to its Board of Directors.

Tevogen Bio Inc. announced the appointment of Mittul Mehta as Chief Information Officer and Head of Tevogen.ai, the newly launched initiative focused on harnessing the potential of artificial intelligence for the enhancement of drug discovery, development, manufacturing, distribution, and patient access.

Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company that is reimagining therapeutic delivery, today announced an update regarding its Investigational New Drug (IND) application.

Quanterix Corporation (NASDAQ: QTRX), a leading provider of ultra-sensitive research products and high-definition diagnostics, today announced the signing of a license agreement with Janssen Sciences Ireland UC (Janssen), a Johnson & Johnson (J&J) Company.

Nucleix, a liquid biopsy company revolutionizing cancer treatment by detecting the disease earlier, today announced participation in the Association Francaise d’Urologie (AFU) Registry of the Therapeutic Management and Follow-Up of Non-Muscle-Invasive Bladder Cancer (TVNIM-AFU).

Scholar Rock today announced that management will host a conference call to discuss its third quarter 2023 financial results and provide a business update on Tuesday, November 7, 2023, at 8:00 a.m. ET.

Qualigen Therapeutics, Inc. (Nasdaq: QLGN) today announces a poster presentation on the Company’s Pan-RAS platform at the American Association for Cancer Research (AACR) Special Conference in Breast Cancer Research, held October 19th to 22nd at the Westin San Diego Bayview.

Schrödinger, Inc. today reported that on October 17, 2023, the company granted (i) non-statutory stock options to purchase 9,150 shares of the company’s common stock to six newly hired employees and (ii) restricted stock units (RSUs) with respect to 11,625 shares of the company’s common stock to 14 newly hired employees.

VUNO Inc., South Korean medical AI company has received 510(k) clearance from the Food and Drug Administration (FDA) for its AI-powered brain quantification device, VUNO Med®-DeepBrain®.